伊沃西尼

伊沃西尼（CAS 1448347-49-6）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的理化数值

在册的记载用途

Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor approved for use in the US and Europe. It is indicated for the treatment of patients with a susceptible IDH1 mutation with: - **Newly Diagnosed Acute Myeloid Leukemia (AML)** in combination [azacitidine] or as monotherapy for the treatment of newly diagnosed AML in adults who have comorbidities that preclude the use of intensive induction chemotherapy. this indication is reserved for adults 75 years or older in the US. - **Relapsed or refractory AML** inIvosidenib is an orally available small molecule inhibitor of mutated isocitrate dehydrogenase-1 that is used as an antineoplastic agent in the treatment of adults of acute myelogenous leukemia (AML). Ivosidenib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to be the cause of rare instances of clinically apparent acute liver injury.

同义词与商品名

Ivosidenib; 1448347-49-6; Tibsovo; AG-120; AG120; Q2PCN8MAM6; ivosidenibum; CHEBI:145430; DTXSID801027928; RefChem:57058; L01XX62; DTXCID801513494; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; RG120

GHS 危害分类

Reported hazard statements	H302 (50%), H360 (50%), H361 (25%), H372 (25%), H373 (50%)

H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]

H360 (50%): May damage fertility or the unborn child [Danger Reproductive toxicity]

公开数据库对它的描述

ivosidenib · CAS 1448347-49-6 · C28H22ClF3N6O3. UNII Q2PCN8MAM6. Solubility: <1 mg/mL.

物理形态与操作说明

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。